Castle Biosciences (CSTL) News Today $25.75 -0.40 (-1.53%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$25.74 0.00 (-0.02%) As of 02/21/2025 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Principal Financial Group Inc. Has $38.26 Million Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL)Principal Financial Group Inc. decreased its position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 6.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,435,665 shares of the company'sFebruary 22 at 3:39 AM | marketbeat.com73,500 Shares in Castle Biosciences, Inc. (NASDAQ:CSTL) Purchased by Hussman Strategic Advisors Inc.Hussman Strategic Advisors Inc. bought a new stake in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 73,500 shares of the company's stock, valued at approximately $1,9February 21 at 6:44 AM | marketbeat.comCastle Biosciences (CSTL) Expected to Announce Earnings on ThursdayCastle Biosciences (NASDAQ:CSTL) will be releasing earnings after the market closes on Thursday, February 27. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=663251)February 20 at 1:26 AM | marketbeat.comKornitzer Capital Management Inc. KS Has $10.23 Million Position in Castle Biosciences, Inc. (NASDAQ:CSTL)Kornitzer Capital Management Inc. KS lessened its position in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 5.7% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 383,974 shares of the company's stock after selling 23,264 shares during the qFebruary 19 at 5:06 AM | marketbeat.comBrokerages Set Castle Biosciences, Inc. (NASDAQ:CSTL) Target Price at $40.29February 19 at 1:13 AM | americanbankingnews.comCastle Biosciences, Inc. (NASDAQ:CSTL) Receives Consensus Rating of "Buy" from AnalystsShares of Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) have been given a consensus recommendation of "Buy" by the seven brokerages that are currently covering the company, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy rating. The average tFebruary 16, 2025 | marketbeat.comLegato Capital Management LLC Has $277,000 Stock Position in Castle Biosciences, Inc. (NASDAQ:CSTL)Legato Capital Management LLC lessened its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 60.5% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 10,395 shares of the company's stock after selling 15,890 sharesFebruary 15, 2025 | marketbeat.comCastle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii®February 12, 2025 | businesswire.comCastle Biosciences director sells $221,636 in stockFebruary 7, 2025 | msn.comCastle Biosciences, Inc. (NASDAQ:CSTL) Director Sells $221,613.39 in StockCastle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) Director Daniel Bradbury sold 7,867 shares of the business's stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $28.17, for a total transaction of $221,613.39. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.February 7, 2025 | marketbeat.comTritonpoint Wealth LLC Cuts Stock Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL)Tritonpoint Wealth LLC reduced its stake in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 17.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 46,637 shares of the company's stock after selling 10,000 shares during the periodFebruary 2, 2025 | marketbeat.comStrong week for Castle Biosciences (NASDAQ:CSTL) shareholders doesn't alleviate pain of three-year lossFebruary 1, 2025 | finance.yahoo.comCastle Biosciences: Buy Rating Affirmed Amid Positive Financial Outlook from Novitas Decision DelayJanuary 28, 2025 | markets.businessinsider.comLake Street raises Castle Biosciences 2025 estimates after Novitas delayJanuary 28, 2025 | markets.businessinsider.comLeerink Partnrs Issues Optimistic Estimate for CSTL EarningsCastle Biosciences, Inc. (NASDAQ:CSTL - Free Report) - Equities researchers at Leerink Partnrs upped their Q4 2024 earnings per share (EPS) estimates for Castle Biosciences in a note issued to investors on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now forecasts that the company willJanuary 23, 2025 | marketbeat.comJPMorgan Chase & Co. Has $1.98 Million Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL)JPMorgan Chase & Co. lifted its holdings in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 165.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 69,409 shares of the company's stock after purchasing an aJanuary 23, 2025 | marketbeat.comLeerink Partnrs Has Positive Outlook of CSTL FY2024 EarningsCastle Biosciences, Inc. (NASDAQ:CSTL - Free Report) - Analysts at Leerink Partnrs increased their FY2024 earnings estimates for shares of Castle Biosciences in a research report issued to clients and investors on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now anticipates that the coJanuary 22, 2025 | marketbeat.comLeerink Partners Keeps Their Buy Rating on Castle Biosciences (CSTL)January 22, 2025 | markets.businessinsider.comCastle Biosciences, Inc. (NASDAQ:CSTL) Given Consensus Recommendation of "Buy" by BrokeragesShares of Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) have received an average rating of "Buy" from the seven ratings firms that are currently covering the stock, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy rating. The average 1-year priceJanuary 22, 2025 | marketbeat.comCastle Biosciences (NASDAQ:CSTL) Trading 8.1% Higher - Time to Buy?Castle Biosciences (NASDAQ:CSTL) Trading Up 8.1% - Here's What HappenedJanuary 21, 2025 | marketbeat.comCastle Biosciences to share data on DecisionDx-SCCJanuary 17, 2025 | markets.businessinsider.comDerek J. Maetzold Sells 986 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) StockCastle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek J. Maetzold sold 986 shares of the company's stock in a transaction on Monday, January 13th. The stock was sold at an average price of $28.03, for a total transaction of $27,637.58. Following the transaction, the insider now owns 80,818 shares of the company's stock, valued at approximately $2,265,328.54. This represents a 1.21 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.January 15, 2025 | marketbeat.comCastle Biosciences stock tumbles following guidance concernsJanuary 13, 2025 | investing.comCastle Biosciences (NASDAQ:CSTL) Trading Down 14% - Here's WhyCastle Biosciences (NASDAQ:CSTL) Shares Down 14% - Should You Sell?January 13, 2025 | marketbeat.comCastle expects FY24 revenue to meet or exceed top end of $320M-$330M guidanceJanuary 13, 2025 | msn.comCastle Biosciences Positioned for Growth After Novitas Resolution and Focus on Core FranchisesJanuary 13, 2025 | markets.businessinsider.comCastle Biosciences Expects To Meet Or Exceed Top End Of FY24 Revenue GuidanceJanuary 13, 2025 | markets.businessinsider.comBarclays PLC Has $1.49 Million Holdings in Castle Biosciences, Inc. (NASDAQ:CSTL)Barclays PLC increased its stake in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 310.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 52,301 shares of the company's stock after purchasing an additionalJanuary 13, 2025 | marketbeat.comCastle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 ResultsJanuary 12, 2025 | businesswire.comHarbor Capital Advisors Inc. Sells 35,407 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)Harbor Capital Advisors Inc. decreased its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 23.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 118,500 shares of the company's stock after selling 35,407 shares durinJanuary 11, 2025 | marketbeat.comCastle Biosciences stock falls following Medicare coverage denialJanuary 10, 2025 | au.investing.comCanaccord Genuity Keeps Their Buy Rating on Castle Biosciences (CSTL)January 10, 2025 | markets.businessinsider.comLake Street Keeps Their Buy Rating on Castle Biosciences (CSTL)January 10, 2025 | markets.businessinsider.comCastle Biosciences (NASDAQ:CSTL) Shares Gap Down - Time to Sell?Castle Biosciences (NASDAQ:CSTL) Shares Gap Down - Here's What HappenedJanuary 10, 2025 | marketbeat.comCastle Biosciences, Inc. (NASDAQ:CSTL) Insider Derek J. Maetzold Sells 2,715 SharesCastle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek J. Maetzold sold 2,715 shares of the business's stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $29.62, for a total value of $80,418.30. Following the transaction, the insider now owns 82,047 shares in the company, valued at $2,430,232.14. This represents a 3.20 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.January 8, 2025 | marketbeat.comCastle Biosciences, Inc. (NASDAQ:CSTL) Director Daniel Bradbury Sells 7,867 SharesCastle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) Director Daniel Bradbury sold 7,867 shares of the business's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $29.14, for a total value of $229,244.38. Following the sale, the director now owns 1,425 shares of the company's stock, valued at $41,524.50. The trade was a 84.66 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.January 8, 2025 | marketbeat.comCastle Biosciences (NASDAQ:CSTL) Shares Up 6.2% - Time to Buy?Castle Biosciences (NASDAQ:CSTL) Trading Up 6.2% - Still a Buy?January 7, 2025 | marketbeat.comCastle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett’s Esophagus TestJanuary 6, 2025 | finance.yahoo.comCastle Biosciences Announces New York State Department of Health Approval of Its TissueCypher® Barrett's Esophagus TestJanuary 6, 2025 | businesswire.comBeyond The Numbers: 7 Analysts Discuss Castle Biosciences StockJanuary 2, 2025 | benzinga.comCastle Biosciences' (CSTL) Overweight Rating Reaffirmed at StephensStephens reaffirmed an "overweight" rating and set a $41.00 target price on shares of Castle Biosciences in a research report on Thursday.January 2, 2025 | marketbeat.comCastle Biosciences, Inc. (NASDAQ:CSTL) Given Average Recommendation of "Buy" by AnalystsCastle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) has been assigned an average rating of "Buy" from the seven analysts that are presently covering the firm, MarketBeat.com reports. Seven research analysts have rated the stock with a buy recommendation. The average twelve-month price objectiDecember 28, 2024 | marketbeat.comCastle Biosciences, Inc. (NASDAQ:CSTL) Shares Bought by Franklin Resources Inc.Franklin Resources Inc. grew its stake in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 87.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 69,382 shares of the company's stock after purchasingDecember 27, 2024 | marketbeat.comState Street Corp Acquires 60,924 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)State Street Corp raised its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 9.8% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 680,001 shares of the company's stock after purchasing an additional 60,924 shares during the perioDecember 24, 2024 | marketbeat.comCastle Biosciences Highlights Progress for its Pipeline Atopic Dermatitis Gene Expression Profile TestDecember 23, 2024 | finance.yahoo.comPrincipal Financial Group Inc. Buys 40,377 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)Principal Financial Group Inc. lifted its position in Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 2.7% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 1,538,520 shares of the company's stock after purchasing an additional 40,377 shares duringDecember 23, 2024 | marketbeat.comCastle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells $265,375.76 in StockDecember 20, 2024 | insidertrades.comInsider Selling: Castle Biosciences, Inc. (NASDAQ:CSTL) Insider Sells 9,364 Shares of StockCastle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek J. Maetzold sold 9,364 shares of Castle Biosciences stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $28.34, for a total transaction of $265,375.76. Following the transaction, the insider now directly owns 84,762 shares in the company, valued at $2,402,155.08. The trade was a 9.95 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.December 19, 2024 | marketbeat.comShort Interest in Castle Biosciences, Inc. (NASDAQ:CSTL) Expands By 7.6%Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) was the recipient of a significant increase in short interest during the month of November. As of November 30th, there was short interest totalling 1,840,000 shares, an increase of 7.6% from the November 15th total of 1,710,000 shares. Based on an average trading volume of 390,900 shares, the days-to-cover ratio is currently 4.7 days.December 17, 2024 | marketbeat.comIndependent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences’ DecisionDx®-Melanoma Test, Contributing to ...December 12, 2024 | businesswire.com Get Castle Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter. Email Address CSTL Media Mentions By Week CSTL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CSTL News Sentiment▼1.060.60▲Average Medical News Sentiment CSTL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CSTL Articles This Week▼65▲CSTL Articles Average Week Get Castle Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LifeStance Health Group News Privia Health Group News Concentra Group Holdings Parent News Teladoc Health News Ardent Health Partners News GeneDx News Addus HomeCare News PACS Group News Progyny News Grail News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CSTL) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Castle Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Castle Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
